|
|||||
|
|
Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain |
|
| Authors: | Sibilia Quilici Jeremy Chancellor Mickael Löthgren Dominique Simon Gérard Said Trong Kim Le Ana Garcia-Cebrian Brigitta Monz |
| Institution: | 1. Health Economics & Outcomes Research, i3 Innovus, Uxbridge, UK 2. Health Economics & Outcomes Research, i3 Innovus, Uxbridge, UK 3. Innovus Research (UK) Ltd, High Wycombe, UK 4. Service de Diabétologie, H?pital de la Pitié, Paris, France 5. Service de Neurologie, H?pital le Kremlin Bicêtre, Paris, France 6. Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA 7. European Health Outcomes, Eli Lilly and Company Limited, Windlesham, Surrey, UK 8. Global Health Economics & Outcomes Research, Boehringer Ingelheim GmbH, Ingelheim, Germany |
| Abstract: | BackgroundFew direct head-to-head comparisons have been conducted between drugs for the treatment of diabetic peripheral neuropathic pain (DPNP). Approved or recommended drugs in this indication include duloxetine (DLX), pregabalin (PGB), gabapentin (GBP) and amitriptyline (AMT). We conducted an indirect meta-analysis to compare the efficacy and tolerability of DLX with PGB and GBP in DPNP, using placebo as a common comparator. |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ | |